tirzepatide hypoglycemia Tirzepatide: A Breakthrough Approach to Losing Weight Safely Tirzepatide, a New Era of

The SAFE Drugs Act, introduced in December 2025, would expand the FDA's power over compounded and unregulated GLP-1 products and the telehealth companies that prescribe them (Dykema analysis)

The pharmacology lines up

It is important for patients to follow their healthcare providers instructions on how to take semaglutide, regardless of the form they are prescribed

It is usually positioned as a functional treatment product with a specific purpose in a skincare routine

Nevertheless, pharmaceutical companies have pursued the twincretin concept, developing GLP-1/GIP dual agonists such as tirzepatide, an analogue biased in favour of GIP over GLP-1 activity [55], and NNC0090-2746, another analogue with balanced GLP-1 and GIP activity [56]

Their role is to inhibit the development of fat cells, encouraging the breakdown of fats, and reducing the synthesis of new fat cells, thereby helping to manage obesity and related metabolic conditions [26, 28]